Jean-Christophe Eymard

Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial

Cora N. Sternberg, Daniel P. Petrylak, Oliver Sartor et al. · Journal of Clinical Oncology · 2009 · 341 citations · Full text

Medicine, Oncology, Pharmacology +13

Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial

Karim Fizazi, Lance C. Pagliaro, Agnès Laplanche et al. · The Lancet Oncology · 2014 · 200 citations · Full text

Medicine, Oncology, Chemotherapy +12

Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer

Isabelle Treilleux, Mónica Arnedos, Claire Cropet et al. · Annals of Oncology · 2014 · 84 citations · Full text

Medicine, Oncology, Pharmacology +17

Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

Karim Fizazi, Gero Kramer, Jean-Christophe Eymard et al. · The Lancet Oncology · 2020 · 65 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase I/II trial of autologous activated macrophages in advanced colorectal cancer

Jean-Christophe Eymard, M. Lopez, A Cattan et al. · European Journal of Cancer · 1996 · 40 citations

Life Sciences, Immunology, Oncology +14